| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psoriasis | 151 | 2024 | 240 | 33.380 |
Why?
|
| Dermatologic Agents | 37 | 2022 | 71 | 8.920 |
Why?
|
| Antibodies, Monoclonal | 53 | 2021 | 1376 | 7.760 |
Why?
|
| Antibodies, Monoclonal, Humanized | 67 | 2024 | 930 | 7.680 |
Why?
|
| Interleukin-23 | 18 | 2023 | 54 | 4.620 |
Why?
|
| Biological Products | 14 | 2023 | 143 | 3.940 |
Why?
|
| Severity of Illness Index | 75 | 2024 | 1802 | 3.880 |
Why?
|
| Arthritis, Psoriatic | 17 | 2023 | 32 | 3.770 |
Why?
|
| Adalimumab | 25 | 2020 | 80 | 3.690 |
Why?
|
| Ustekinumab | 18 | 2021 | 47 | 3.020 |
Why?
|
| Double-Blind Method | 56 | 2024 | 1824 | 2.830 |
Why?
|
| Treatment Outcome | 81 | 2024 | 7998 | 2.810 |
Why?
|
| Interleukin-17 | 8 | 2019 | 101 | 2.270 |
Why?
|
| Quality of Life | 27 | 2023 | 1585 | 2.260 |
Why?
|
| Th17 Cells | 3 | 2024 | 80 | 1.900 |
Why?
|
| Interleukin-12 | 13 | 2023 | 108 | 1.840 |
Why?
|
| Skin Diseases | 7 | 2020 | 166 | 1.580 |
Why?
|
| Humans | 172 | 2024 | 86656 | 1.530 |
Why?
|
| Immunologic Factors | 9 | 2014 | 170 | 1.500 |
Why?
|
| Adult | 86 | 2024 | 25656 | 1.450 |
Why?
|
| Middle Aged | 85 | 2024 | 25035 | 1.340 |
Why?
|
| Tumor Necrosis Factor-alpha | 18 | 2020 | 683 | 1.300 |
Why?
|
| Immunoglobulin G | 14 | 2018 | 456 | 1.220 |
Why?
|
| Male | 95 | 2024 | 40983 | 1.210 |
Why?
|
| Recombinant Fusion Proteins | 9 | 2008 | 557 | 1.190 |
Why?
|
| Female | 95 | 2023 | 44546 | 1.120 |
Why?
|
| Patient Reported Outcome Measures | 5 | 2020 | 166 | 1.100 |
Why?
|
| Receptors, Tumor Necrosis Factor | 13 | 2011 | 88 | 1.090 |
Why?
|
| Interleukin-23 Subunit p19 | 3 | 2019 | 7 | 1.070 |
Why?
|
| Methotrexate | 9 | 2023 | 249 | 1.060 |
Why?
|
| Piperidines | 4 | 2020 | 181 | 1.000 |
Why?
|
| Pyrroles | 3 | 2019 | 184 | 0.980 |
Why?
|
| Withholding Treatment | 4 | 2019 | 112 | 0.970 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2019 | 339 | 0.960 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2019 | 166 | 0.950 |
Why?
|
| Pyrimidines | 4 | 2020 | 370 | 0.910 |
Why?
|
| Chronic Disease | 15 | 2023 | 973 | 0.880 |
Why?
|
| Drug Administration Schedule | 17 | 2021 | 916 | 0.860 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2022 | 243 | 0.840 |
Why?
|
| Anxiety | 3 | 2020 | 287 | 0.800 |
Why?
|
| Skin Neoplasms | 11 | 2020 | 546 | 0.790 |
Why?
|
| Immunosuppressive Agents | 10 | 2019 | 977 | 0.780 |
Why?
|
| Hidradenitis Suppurativa | 2 | 2019 | 11 | 0.770 |
Why?
|
| Liver Diseases | 5 | 2020 | 239 | 0.760 |
Why?
|
| Depression | 6 | 2020 | 473 | 0.750 |
Why?
|
| Clinical Trials as Topic | 5 | 2021 | 1169 | 0.740 |
Why?
|
| Dose-Response Relationship, Drug | 17 | 2018 | 1961 | 0.720 |
Why?
|
| Uveitis | 2 | 2019 | 29 | 0.710 |
Why?
|
| Interleukins | 1 | 2019 | 134 | 0.660 |
Why?
|
| Etanercept | 15 | 2019 | 32 | 0.650 |
Why?
|
| Thalidomide | 4 | 2024 | 54 | 0.630 |
Why?
|
| Immunotherapy | 5 | 2023 | 629 | 0.610 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2022 | 865 | 0.610 |
Why?
|
| Biological Therapy | 4 | 2020 | 45 | 0.600 |
Why?
|
| TYK2 Kinase | 3 | 2022 | 7 | 0.600 |
Why?
|
| Maintenance Chemotherapy | 4 | 2020 | 76 | 0.550 |
Why?
|
| Placebos | 9 | 2019 | 218 | 0.530 |
Why?
|
| T-Lymphocytes | 10 | 2007 | 1195 | 0.530 |
Why?
|
| Aged | 36 | 2023 | 18421 | 0.510 |
Why?
|
| Crohn Disease | 3 | 2019 | 730 | 0.470 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2011 | 199 | 0.470 |
Why?
|
| Candidiasis, Oral | 2 | 2024 | 4 | 0.460 |
Why?
|
| Antibodies, Blocking | 1 | 2013 | 21 | 0.460 |
Why?
|
| Phototherapy | 5 | 2019 | 35 | 0.450 |
Why?
|
| Colitis, Ulcerative | 2 | 2019 | 711 | 0.450 |
Why?
|
| Bowen's Disease | 3 | 1997 | 9 | 0.430 |
Why?
|
| Cross-Over Studies | 5 | 2020 | 399 | 0.420 |
Why?
|
| Dermatology | 4 | 2020 | 35 | 0.390 |
Why?
|
| Time Factors | 13 | 2018 | 5211 | 0.380 |
Why?
|
| Heterocyclic Compounds | 2 | 2021 | 17 | 0.370 |
Why?
|
| Injections, Subcutaneous | 9 | 2021 | 117 | 0.370 |
Why?
|
| Adolescent | 16 | 2023 | 8984 | 0.370 |
Why?
|
| Keratolytic Agents | 3 | 2008 | 4 | 0.360 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2014 | 589 | 0.360 |
Why?
|
| Aged, 80 and over | 11 | 2020 | 6513 | 0.360 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2019 | 263 | 0.350 |
Why?
|
| Retreatment | 4 | 2017 | 107 | 0.350 |
Why?
|
| PUVA Therapy | 4 | 2009 | 24 | 0.340 |
Why?
|
| Pruritus | 6 | 2020 | 26 | 0.340 |
Why?
|
| Follow-Up Studies | 11 | 2019 | 3642 | 0.330 |
Why?
|
| Drug Substitution | 2 | 2018 | 25 | 0.310 |
Why?
|
| Recurrence | 3 | 2019 | 1139 | 0.300 |
Why?
|
| Risk Assessment | 9 | 2018 | 2264 | 0.300 |
Why?
|
| Young Adult | 11 | 2023 | 5980 | 0.300 |
Why?
|
| Patient Education as Topic | 3 | 2020 | 351 | 0.270 |
Why?
|
| Langerhans Cells | 1 | 2005 | 13 | 0.270 |
Why?
|
| Epidermis | 2 | 2005 | 100 | 0.270 |
Why?
|
| Cyclosporine | 6 | 2020 | 234 | 0.270 |
Why?
|
| Cardiovascular Diseases | 8 | 2019 | 827 | 0.260 |
Why?
|
| Drug Eruptions | 2 | 1996 | 35 | 0.260 |
Why?
|
| Prognosis | 5 | 2018 | 3680 | 0.260 |
Why?
|
| Autoimmune Diseases | 2 | 1998 | 241 | 0.260 |
Why?
|
| Carcinoma, Basal Cell | 4 | 2012 | 54 | 0.260 |
Why?
|
| Inflammatory Bowel Diseases | 5 | 2024 | 549 | 0.260 |
Why?
|
| Patient Advocacy | 1 | 2005 | 49 | 0.250 |
Why?
|
| Delphi Technique | 2 | 2018 | 80 | 0.250 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2012 | 1077 | 0.250 |
Why?
|
| Autoantibodies | 2 | 2003 | 267 | 0.250 |
Why?
|
| Graft vs Host Disease | 1 | 2007 | 365 | 0.250 |
Why?
|
| Metabolic Syndrome | 4 | 2019 | 142 | 0.240 |
Why?
|
| Health Care Costs | 2 | 2016 | 239 | 0.240 |
Why?
|
| Laser Therapy | 2 | 1996 | 142 | 0.240 |
Why?
|
| Certolizumab Pegol | 2 | 2020 | 19 | 0.230 |
Why?
|
| Biomarkers | 3 | 2021 | 1718 | 0.230 |
Why?
|
| Clinical Trials, Phase III as Topic | 6 | 2024 | 172 | 0.230 |
Why?
|
| Skin | 7 | 2023 | 554 | 0.230 |
Why?
|
| Hand Dermatoses | 2 | 2020 | 9 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 1037 | 0.230 |
Why?
|
| Terminology as Topic | 1 | 2005 | 217 | 0.230 |
Why?
|
| Erythema | 2 | 2020 | 27 | 0.220 |
Why?
|
| Dermatitis, Atopic | 1 | 2023 | 52 | 0.220 |
Why?
|
| Incidence | 4 | 2018 | 1578 | 0.220 |
Why?
|
| ROC Curve | 2 | 2016 | 752 | 0.220 |
Why?
|
| Patients | 1 | 2023 | 100 | 0.210 |
Why?
|
| Arthralgia | 2 | 2019 | 36 | 0.210 |
Why?
|
| Macrolides | 1 | 2001 | 31 | 0.210 |
Why?
|
| Syringes | 1 | 2021 | 13 | 0.200 |
Why?
|
| Liver Cirrhosis | 2 | 2020 | 300 | 0.200 |
Why?
|
| Jaundice | 2 | 2020 | 14 | 0.200 |
Why?
|
| Sunscreening Agents | 1 | 2001 | 7 | 0.200 |
Why?
|
| Consensus | 2 | 2023 | 336 | 0.200 |
Why?
|
| Mental Health | 2 | 2019 | 162 | 0.190 |
Why?
|
| Administration, Oral | 3 | 2018 | 684 | 0.190 |
Why?
|
| Photochemotherapy | 2 | 2019 | 97 | 0.190 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2003 | 425 | 0.190 |
Why?
|
| Xanthomatosis | 1 | 2020 | 5 | 0.190 |
Why?
|
| Hemochromatosis | 1 | 2020 | 11 | 0.190 |
Why?
|
| Anticarcinogenic Agents | 1 | 2001 | 70 | 0.190 |
Why?
|
| Cohort Studies | 3 | 2023 | 2768 | 0.190 |
Why?
|
| Respiratory Tract Infections | 2 | 2019 | 105 | 0.190 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2020 | 29 | 0.190 |
Why?
|
| Psychometrics | 2 | 2020 | 327 | 0.180 |
Why?
|
| Tacrolimus | 1 | 2001 | 373 | 0.180 |
Why?
|
| Hepatitis B, Chronic | 1 | 2020 | 32 | 0.180 |
Why?
|
| Hemangioma | 1 | 2020 | 60 | 0.180 |
Why?
|
| Evidence-Based Medicine | 6 | 2020 | 429 | 0.180 |
Why?
|
| Infliximab | 6 | 2019 | 151 | 0.180 |
Why?
|
| Electronic Health Records | 1 | 2023 | 320 | 0.180 |
Why?
|
| Obesity | 5 | 2019 | 964 | 0.180 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 1001 | 0.180 |
Why?
|
| Antirheumatic Agents | 2 | 2012 | 54 | 0.180 |
Why?
|
| Complementary Therapies | 1 | 2020 | 54 | 0.180 |
Why?
|
| CD11 Antigens | 5 | 2006 | 14 | 0.180 |
Why?
|
| Foundations | 4 | 2020 | 25 | 0.180 |
Why?
|
| United States | 10 | 2020 | 6681 | 0.170 |
Why?
|
| Headache | 1 | 2019 | 73 | 0.170 |
Why?
|
| Epitopes | 3 | 1998 | 255 | 0.170 |
Why?
|
| Hepatitis C, Chronic | 1 | 2020 | 126 | 0.170 |
Why?
|
| Remission Induction | 4 | 2020 | 722 | 0.170 |
Why?
|
| Digestive System Diseases | 1 | 1998 | 18 | 0.160 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2018 | 19 | 0.160 |
Why?
|
| Body Surface Area | 1 | 2018 | 36 | 0.160 |
Why?
|
| Social Class | 1 | 2018 | 128 | 0.160 |
Why?
|
| Fingers | 2 | 1996 | 68 | 0.150 |
Why?
|
| Epidermolysis Bullosa Acquisita | 1 | 1997 | 2 | 0.150 |
Why?
|
| Photopheresis | 1 | 1997 | 12 | 0.150 |
Why?
|
| Disease Progression | 3 | 2013 | 1532 | 0.150 |
Why?
|
| Fractures, Spontaneous | 1 | 2017 | 11 | 0.150 |
Why?
|
| Linear Models | 1 | 2018 | 422 | 0.150 |
Why?
|
| Physician's Role | 1 | 2019 | 179 | 0.150 |
Why?
|
| Patient Preference | 1 | 2018 | 105 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 3 | 2006 | 159 | 0.150 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1997 | 100 | 0.140 |
Why?
|
| Absenteeism | 1 | 2016 | 9 | 0.140 |
Why?
|
| Pain | 2 | 2018 | 391 | 0.140 |
Why?
|
| Inpatients | 2 | 2016 | 298 | 0.140 |
Why?
|
| Clonazepam | 1 | 1996 | 3 | 0.140 |
Why?
|
| Lymphocyte Activation | 5 | 2003 | 728 | 0.140 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 502 | 0.140 |
Why?
|
| GABA Modulators | 1 | 1996 | 9 | 0.140 |
Why?
|
| Efficiency | 1 | 2016 | 39 | 0.140 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 1996 | 19 | 0.140 |
Why?
|
| Mycosis Fungoides | 1 | 1996 | 23 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 1997 | 2438 | 0.140 |
Why?
|
| Combined Modality Therapy | 5 | 2020 | 1686 | 0.140 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2015 | 10 | 0.140 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 895 | 0.140 |
Why?
|
| Fluoxetine | 1 | 1996 | 42 | 0.130 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2015 | 3 | 0.130 |
Why?
|
| Osteoporosis | 1 | 2017 | 121 | 0.130 |
Why?
|
| Sarcoma, Kaposi | 1 | 1995 | 19 | 0.130 |
Why?
|
| Administration, Cutaneous | 3 | 2020 | 58 | 0.130 |
Why?
|
| Astrocytes | 3 | 2002 | 139 | 0.120 |
Why?
|
| Patient Satisfaction | 3 | 2014 | 455 | 0.120 |
Why?
|
| Doxorubicin | 1 | 1995 | 295 | 0.120 |
Why?
|
| Acitretin | 3 | 2020 | 4 | 0.120 |
Why?
|
| Models, Statistical | 1 | 2017 | 575 | 0.120 |
Why?
|
| Coronary Artery Disease | 2 | 2008 | 350 | 0.120 |
Why?
|
| Hospitalization | 2 | 2016 | 851 | 0.120 |
Why?
|
| Retrospective Studies | 4 | 2023 | 8495 | 0.120 |
Why?
|
| Sickness Impact Profile | 1 | 2013 | 27 | 0.120 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 84 | 0.110 |
Why?
|
| Hospital Mortality | 3 | 2016 | 350 | 0.110 |
Why?
|
| Disability Evaluation | 1 | 2013 | 136 | 0.110 |
Why?
|
| Child | 6 | 2023 | 6928 | 0.110 |
Why?
|
| Wound Healing | 2 | 2006 | 344 | 0.110 |
Why?
|
| Rheumatic Diseases | 1 | 2012 | 20 | 0.100 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2011 | 22 | 0.100 |
Why?
|
| Inflammation | 2 | 2008 | 923 | 0.100 |
Why?
|
| Cross-Sectional Studies | 4 | 2018 | 1621 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 372 | 0.100 |
Why?
|
| Acute Disease | 2 | 2023 | 826 | 0.100 |
Why?
|
| Safety Management | 1 | 2011 | 56 | 0.100 |
Why?
|
| Long-Term Care | 1 | 2011 | 61 | 0.100 |
Why?
|
| SEER Program | 1 | 2011 | 190 | 0.100 |
Why?
|
| Keratinocytes | 2 | 2009 | 143 | 0.090 |
Why?
|
| Global Health | 2 | 2012 | 193 | 0.090 |
Why?
|
| Academies and Institutes | 2 | 2020 | 31 | 0.090 |
Why?
|
| Opportunistic Infections | 3 | 2018 | 59 | 0.090 |
Why?
|
| Health Status Indicators | 2 | 2007 | 105 | 0.090 |
Why?
|
| Drug Approval | 1 | 2009 | 62 | 0.080 |
Why?
|
| Depressive Disorder | 1 | 2010 | 218 | 0.080 |
Why?
|
| United States Food and Drug Administration | 1 | 2009 | 127 | 0.080 |
Why?
|
| Cytokines | 2 | 2003 | 778 | 0.080 |
Why?
|
| Comorbidity | 3 | 2019 | 944 | 0.080 |
Why?
|
| Placebo Effect | 1 | 2008 | 31 | 0.080 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 376 | 0.080 |
Why?
|
| Logistic Models | 2 | 2016 | 1188 | 0.080 |
Why?
|
| Dyslipidemias | 2 | 2019 | 109 | 0.080 |
Why?
|
| B7-1 Antigen | 2 | 1998 | 75 | 0.080 |
Why?
|
| CD2 Antigens | 1 | 2007 | 22 | 0.070 |
Why?
|
| Computer Graphics | 2 | 2003 | 100 | 0.070 |
Why?
|
| Immune System | 1 | 2007 | 93 | 0.070 |
Why?
|
| Etretinate | 1 | 2006 | 4 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2007 | 219 | 0.070 |
Why?
|
| Syndrome | 2 | 1998 | 446 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 1 | 2007 | 286 | 0.070 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2007 | 136 | 0.070 |
Why?
|
| Animals | 7 | 2013 | 26590 | 0.070 |
Why?
|
| Candidiasis | 2 | 2016 | 36 | 0.070 |
Why?
|
| Vaccination | 1 | 2007 | 254 | 0.070 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2007 | 173 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2005 | 2231 | 0.070 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2005 | 22 | 0.070 |
Why?
|
| Cell Count | 1 | 2005 | 195 | 0.070 |
Why?
|
| Biopsy | 2 | 2007 | 1163 | 0.070 |
Why?
|
| Registries | 2 | 2020 | 703 | 0.070 |
Why?
|
| Surveys and Questionnaires | 4 | 2016 | 2504 | 0.070 |
Why?
|
| Neoplasms | 4 | 2019 | 2898 | 0.070 |
Why?
|
| Neutropenia | 2 | 2016 | 215 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2018 | 4214 | 0.060 |
Why?
|
| Mice, SCID | 1 | 2005 | 252 | 0.060 |
Why?
|
| Fatigue | 1 | 2006 | 174 | 0.060 |
Why?
|
| Skin Transplantation | 1 | 2005 | 172 | 0.060 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2007 | 261 | 0.060 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 363 | 0.060 |
Why?
|
| Interferon-gamma | 4 | 2002 | 444 | 0.060 |
Why?
|
| Patient Selection | 1 | 2008 | 686 | 0.060 |
Why?
|
| Nova Scotia | 1 | 2003 | 2 | 0.060 |
Why?
|
| Bacteriophage phi X 174 | 1 | 2003 | 2 | 0.060 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2003 | 23 | 0.060 |
Why?
|
| Tetanus Toxoid | 1 | 2003 | 10 | 0.060 |
Why?
|
| Injections, Intramuscular | 1 | 2003 | 62 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 2 | 2002 | 139 | 0.060 |
Why?
|
| Lymphocyte Count | 1 | 2003 | 94 | 0.060 |
Why?
|
| Life Style | 2 | 2019 | 189 | 0.060 |
Why?
|
| Eye Diseases | 2 | 2002 | 53 | 0.060 |
Why?
|
| Skin, Artificial | 1 | 2002 | 8 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2004 | 178 | 0.060 |
Why?
|
| Drug Design | 1 | 2003 | 124 | 0.060 |
Why?
|
| Length of Stay | 2 | 2016 | 704 | 0.060 |
Why?
|
| Self Report | 2 | 2015 | 288 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2002 | 1015 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2023 | 160 | 0.050 |
Why?
|
| Forecasting | 1 | 2003 | 305 | 0.050 |
Why?
|
| Illinois | 1 | 2003 | 462 | 0.050 |
Why?
|
| Stroke | 1 | 2011 | 965 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2019 | 2379 | 0.050 |
Why?
|
| Pancytopenia | 1 | 2002 | 23 | 0.050 |
Why?
|
| Risk Factors | 4 | 2008 | 5420 | 0.050 |
Why?
|
| Spondylitis, Ankylosing | 2 | 2012 | 24 | 0.050 |
Why?
|
| Vitamin D | 2 | 2018 | 261 | 0.050 |
Why?
|
| Arthritis, Juvenile | 2 | 2012 | 32 | 0.050 |
Why?
|
| Infant | 2 | 2019 | 3047 | 0.050 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2002 | 107 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2002 | 224 | 0.050 |
Why?
|
| Collagen | 1 | 2002 | 269 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 167 | 0.050 |
Why?
|
| California | 2 | 2015 | 138 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2019 | 3613 | 0.050 |
Why?
|
| Sunlight | 1 | 2001 | 26 | 0.050 |
Why?
|
| Interferon Type I | 1 | 2021 | 175 | 0.050 |
Why?
|
| Pemphigus, Benign Familial | 1 | 2000 | 1 | 0.050 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2011 | 24 | 0.050 |
Why?
|
| Nausea | 1 | 2002 | 175 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 508 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2016 | 816 | 0.050 |
Why?
|
| Pneumonia | 1 | 2002 | 179 | 0.050 |
Why?
|
| Anthralin | 1 | 2019 | 1 | 0.050 |
Why?
|
| Coal Tar | 1 | 2019 | 1 | 0.050 |
Why?
|
| Nicotinic Acids | 1 | 2019 | 8 | 0.050 |
Why?
|
| Retinoids | 1 | 2019 | 17 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 435 | 0.040 |
Why?
|
| Demography | 1 | 2020 | 177 | 0.040 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2000 | 49 | 0.040 |
Why?
|
| Hemangioendothelioma | 1 | 1999 | 9 | 0.040 |
Why?
|
| Antigens, CD | 2 | 2002 | 458 | 0.040 |
Why?
|
| Calcineurin Inhibitors | 1 | 2019 | 54 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2019 | 87 | 0.040 |
Why?
|
| Lymphoma | 2 | 2008 | 262 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 118 | 0.040 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2019 | 19 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 150 | 0.040 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2019 | 20 | 0.040 |
Why?
|
| Mice | 5 | 2005 | 11356 | 0.040 |
Why?
|
| Foot Dermatoses | 1 | 2018 | 3 | 0.040 |
Why?
|
| Nails | 1 | 2018 | 7 | 0.040 |
Why?
|
| Scalp Dermatoses | 1 | 2018 | 10 | 0.040 |
Why?
|
| Pancreatic Diseases | 1 | 1998 | 51 | 0.040 |
Why?
|
| Canada | 2 | 2010 | 204 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2001 | 427 | 0.040 |
Why?
|
| Income | 1 | 2018 | 76 | 0.040 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 1998 | 57 | 0.040 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2019 | 103 | 0.040 |
Why?
|
| Myelin Sheath | 1 | 1998 | 84 | 0.040 |
Why?
|
| Apoptosis | 2 | 2007 | 1683 | 0.040 |
Why?
|
| Educational Status | 1 | 2018 | 190 | 0.040 |
Why?
|
| Isotretinoin | 1 | 1997 | 23 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1997 | 68 | 0.040 |
Why?
|
| Insulin Resistance | 1 | 2019 | 377 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 1999 | 342 | 0.040 |
Why?
|
| Overweight | 1 | 2018 | 118 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 1998 | 209 | 0.040 |
Why?
|
| Basement Membrane | 1 | 1997 | 54 | 0.040 |
Why?
|
| Ovalbumin | 1 | 1997 | 109 | 0.040 |
Why?
|
| Presenteeism | 1 | 2016 | 1 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 1997 | 234 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2010 | 911 | 0.040 |
Why?
|
| Health Surveys | 1 | 2017 | 239 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 72 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2018 | 129 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 1997 | 106 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 173 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 204 | 0.030 |
Why?
|
| Georgia | 1 | 2015 | 34 | 0.030 |
Why?
|
| Colorado | 1 | 2015 | 35 | 0.030 |
Why?
|
| Washington | 1 | 2015 | 48 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2016 | 117 | 0.030 |
Why?
|
| Foot | 1 | 1995 | 50 | 0.030 |
Why?
|
| Liposomes | 1 | 1995 | 91 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2019 | 415 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 1996 | 146 | 0.030 |
Why?
|
| Janus Kinase 3 | 1 | 2014 | 9 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1995 | 78 | 0.030 |
Why?
|
| Single-Blind Method | 2 | 2006 | 153 | 0.030 |
Why?
|
| Drug Carriers | 1 | 1995 | 82 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 1997 | 428 | 0.030 |
Why?
|
| Hepatitis, Viral, Human | 2 | 2009 | 25 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1995 | 429 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2015 | 256 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 680 | 0.030 |
Why?
|
| Hand | 1 | 1995 | 130 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 1994 | 188 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 567 | 0.030 |
Why?
|
| Eye Neoplasms | 1 | 1993 | 27 | 0.030 |
Why?
|
| Macrophages | 2 | 2007 | 557 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2014 | 256 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2008 | 769 | 0.030 |
Why?
|
| Patient Participation | 1 | 2015 | 216 | 0.030 |
Why?
|
| Skin Diseases, Infectious | 1 | 2012 | 13 | 0.030 |
Why?
|
| Focus Groups | 1 | 2013 | 155 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1538 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 2012 | 28 | 0.030 |
Why?
|
| Brain | 1 | 2002 | 2216 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 1996 | 1564 | 0.030 |
Why?
|
| Case Management | 1 | 2011 | 24 | 0.020 |
Why?
|
| Health Status | 1 | 2013 | 360 | 0.020 |
Why?
|
| Cognition | 1 | 2015 | 571 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2706 | 0.020 |
Why?
|
| Hypertension | 1 | 2019 | 1142 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1996 | 1313 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 674 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 270 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2002 | 158 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2009 | 95 | 0.020 |
Why?
|
| Ultraviolet Therapy | 1 | 2008 | 15 | 0.020 |
Why?
|
| Reference Values | 1 | 2010 | 674 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 1239 | 0.020 |
Why?
|
| Nasopharyngitis | 1 | 2008 | 2 | 0.020 |
Why?
|
| Survival Rate | 2 | 2005 | 1864 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 1375 | 0.020 |
Why?
|
| Tuberculin Test | 1 | 2007 | 5 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2007 | 14 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2007 | 93 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 1993 | 763 | 0.020 |
Why?
|
| Sweden | 1 | 2007 | 40 | 0.020 |
Why?
|
| Antibodies, Antinuclear | 1 | 2007 | 83 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 190 | 0.020 |
Why?
|
| Medical Records | 1 | 2007 | 119 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2007 | 211 | 0.020 |
Why?
|
| International Cooperation | 1 | 2007 | 127 | 0.020 |
Why?
|
| Physical Examination | 1 | 2007 | 149 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2008 | 228 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2009 | 336 | 0.020 |
Why?
|
| Ontario | 1 | 2006 | 52 | 0.020 |
Why?
|
| Fibrosis | 1 | 2006 | 203 | 0.020 |
Why?
|
| Burn Units | 1 | 2005 | 21 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2002 | 2819 | 0.020 |
Why?
|
| Self-Assessment | 1 | 2005 | 47 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2005 | 194 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 234 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2006 | 301 | 0.020 |
Why?
|
| Buttocks | 1 | 2003 | 10 | 0.020 |
Why?
|
| Scrotum | 1 | 2003 | 17 | 0.010 |
Why?
|
| Smoking | 1 | 2008 | 609 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2007 | 425 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 297 | 0.010 |
Why?
|
| Thigh | 1 | 2003 | 38 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 308 | 0.010 |
Why?
|
| Biomedical Engineering | 1 | 2002 | 20 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2007 | 376 | 0.010 |
Why?
|
| Mohs Surgery | 1 | 2002 | 21 | 0.010 |
Why?
|
| Myelin Proteolipid Protein | 1 | 2002 | 2 | 0.010 |
Why?
|
| Hybridomas | 1 | 2002 | 74 | 0.010 |
Why?
|
| Pregnancy | 1 | 2009 | 2894 | 0.010 |
Why?
|
| Clone Cells | 1 | 2002 | 213 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2002 | 164 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2002 | 249 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2002 | 163 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2002 | 132 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2002 | 321 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2007 | 1458 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 1753 | 0.010 |
Why?
|
| HIV Infections | 1 | 2009 | 772 | 0.010 |
Why?
|
| Sweat Glands | 1 | 2000 | 6 | 0.010 |
Why?
|
| Pain, Postoperative | 1 | 2002 | 240 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2002 | 460 | 0.010 |
Why?
|
| Injections | 1 | 2000 | 109 | 0.010 |
Why?
|
| Axilla | 1 | 2000 | 99 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1999 | 307 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1999 | 303 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1999 | 391 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1999 | 376 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 1998 | 168 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 696 | 0.010 |
Why?
|
| Cell Line | 1 | 2002 | 2469 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 1041 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1999 | 790 | 0.010 |
Why?
|
| B7-2 Antigen | 1 | 1997 | 40 | 0.010 |
Why?
|
| Abatacept | 1 | 1997 | 83 | 0.010 |
Why?
|
| Nail Diseases | 1 | 1996 | 5 | 0.010 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 1996 | 8 | 0.010 |
Why?
|
| CTLA-4 Antigen | 1 | 1997 | 135 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 1997 | 141 | 0.010 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 1996 | 39 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1996 | 106 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 1998 | 503 | 0.010 |
Why?
|
| Gene Expression | 1 | 1999 | 1284 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1997 | 1047 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1996 | 230 | 0.010 |
Why?
|
| Vitreous Body | 1 | 1993 | 54 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1997 | 2062 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1997 | 3030 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1997 | 1981 | 0.010 |
Why?
|